Tigecycline: a case study

Bibliography

• DUGGAR BM: Aureomycin: product of continuing search for new antibiotics. Ann. NY Acad. Sci. (1948) 51:177-181.
   PubMed Web of Science ®Google Scholar
• CHOPRA I, HAWKEY PM, HINTON M: Tetracyclines, molecular and clinical aspects. J. Antimicrob. Chemother (1992) 29:245-277.
   Google Scholar
• COL NF, O’CONNOR RW: Estimating worldwide current antibiotic usage: report of Task Force 1. Rev. Infect.Dis. (1987) 3:S232-243.
   Google Scholar
• NEU HC: The crisis in antibiotic resistance. Science (1992). 257:1064-1073.
   PubMed Web of Science ®Google Scholar
• SCHNAPPINGER D, HILLEN W: Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch. Microbiology (1996) 165:359-369.
   Google Scholar
• RAMAKRISHNAN V: Ribosome structure and the mechanism of translation. Cell (2002) 108(4):557-572.
   PubMed Web of Science ®Google Scholar
• MOORE PB, STEITZ TA: The involvement of RNA in ribosome function. Nature (2002) 418(6894):229-235.
   PubMed Web of Science ®Google Scholar
• GOLDMAN RA, HASAN T, HALL CC, STRYCHARZ WA, COOPERMAN BS: Photoincorporation of tetracycline into Escherichia coli ribosomes. Identification of the major proteins photolabeled by native tetracycline and tetracycline photoproducts and implications for the inhibitory action of tetracycline on protein synthesis. Biochem. (1983) 22(2):359-368.
   PubMed Web of Science ®Google Scholar
• BAUER G, BERENS C, PROJAN SJ, HILLEN W: Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. (2004) 53(4):592-599.
   Google Scholar
• RASMUSSEN BA, NOLLER HF, DAUBRESSE G et al.: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome. Antimicrob. Agents Chemother. (1991) 35:2306-2311.
   Web of Science ®Google Scholar
• OCHIYA B, GORDON GG, MCNICHOLAS P, ELLESTAD G, CHOPRA I: Evidence that tetracycline analogs whose primary target is not the bacterial ribosome cause lyses of Escherichia coli. Antimicrob. Agents Chemother. (1992) 36:913-919.
   Web of Science ®Google Scholar
• SPEER BS, BEDZYK L, SALYERS AA: Evidence that a novel tetracycline resistance gene found on two bacteroides transposons encodes an NADP-requiring oxidoreductase. J. Bacteriol (1991) 173:176-183.
   Google Scholar
• LEVY SB, MCMURRY LM, BURDETT V et al.: Nomenclature for tetracycline resistance determinants. Antimicrob. Agents Chemother. (1989) 33(8):1373-1374.
   Web of Science ®Google Scholar
• LEVY SB: Tetracycline resistance determinants are widespread. ASM News (1988) 54:418-421.
   Google Scholar
• YAMAGUCHI A, UDAGAWA T, SAWAI T: Transport of divalent cations with tetracycline as mediated by the transposon Tn10-encoded tetracycline resistance protein. J. Biol. Chem. (1990) 265:4809-4813.
   PubMed Web of Science ®Google Scholar
• BURDETT V: Tet(M)-promoted release of tetracycline rfom ribosomes is GTP dependent. J. Bacteriol (1996) 178:3246-3251.
   Google Scholar
• SUM PE, SUM FW, PROJAN SJ: Recent developments in tetracycline antibiotics. Curr. Pharm. Des. (1998) 4:119-132.
   Web of Science ®Google Scholar
• CHAREST M, LERNER CD, BRUBAKER JD, SIEGEl DR, DIONICIO R, MYERS AG: A convergent enantioselective route to structurally diverse 6 - deoxytetracycline antibiotics. Science (2005) 308:395-398.
   PubMed Web of Science ®Google Scholar
• SUM PE, LEE VJ, TALLY FP: Synthesis of novel tetracycline derivatives with substitution at the C-8 position. Tetrahedon Lett. (1994) 35:1835-1836.
   Web of Science ®Google Scholar
• RASMUSSEN BA, GLUZMAN Y, TALLY FP: Inhibition of protein synthesis on tetracycline-resistant TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Chemother Agents (1993) 38:1658-1660.
   Google Scholar
• LEDERER T, KINTRUP M, TAKAHASHI M et al.: Tetracycline analogs affecting binding to Tn10-Encoded Tet repressor trigger the same mechanism of induction. Biochem. (1996) 35:7439-7446.
   PubMed Web of Science ®Google Scholar
• SUM PE, ROSS, AT, PETERSEN PJ, TESTA RT: Synthesis and antibacterial activity of 9-substituted minocycline derivatives. Bioorg. Med. Chem. Lett (2006) 16:400-403.
   Web of Science ®Google Scholar
• SUM PE, LEE VJ, TESTA RT et al.: Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J. Med. Chem. (1994) 37:184-188.
   PubMed Web of Science ®Google Scholar
• SUM PE, PETERSEN PJ: Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett (1999) 9:1459-1462.
   Web of Science ®Google Scholar
• TESTA RT, PETERSEN PJ, JACOBUS NV, SUM PE, LEE V, TALLY FP: In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother. (1993) 37:2270-2277.
   Web of Science ®Google Scholar
• ELIOPOULOS GM, WENNERSTEN CB, COLE G, MOELLERING RC: In vitro activity of two glycylcyclines against gram-positive bacteria. Antimicrob. Agents Chemother. (1994) 38:534-541.
   Web of Science ®Google Scholar
• GOLDSTEIN FW, KITZIS MD, ACAR JF: N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-deoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci. Antimicrob. Agents Chemother (1994) 38:2218-2220.
   Web of Science ®Google Scholar
• KENNY GE, CARTWRIGHT FD: Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines. Antimicrob. Agents Chemother. (1994) 38:2628-2632.
   Web of Science ®Google Scholar
• NORD CD, LINDMARK A, PERSSON I: In vitro activity of DMG-MINO and DMG-DMDOT, two new glycylcyclines, against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. (1993) 12:784-786.
   Google Scholar
• WEXLER HM, MOLITORIS E, FINEGOLD SM: In vitro activities of two new glycylcyclines, N, N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria. Antimicrob. Agents Chemother. (1994) 38:2513-2515.
   Web of Science ®Google Scholar
• WISE R, ANDREWS JM: In vitro activities of two glycylcyclines. Antimicrob. Agents Chemother. (1994) 38:1096-1102.
   Web of Science ®Google Scholar
• PETERSEN PJ, JACOBUS NV, WEISS WJ, SUM PE, TESTA RT: In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. (1999) 43:738-744.
   Web of Science ®Google Scholar
• BETRIU C, CULEBRAS E, RODRIGUEZ-AVIAL I, GOMEZ M, SANCHEZ BA, PICAZO JJ: In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob. Agents Chemother. (2004) 48:323-325.
   Web of Science ®Google Scholar
• BETRIU C, RODRIGUEZ-AVIAL I, SANCHEZ B et al.: In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. (2002) 46:892-895.
   Web of Science ®Google Scholar
• BIEDENBACH D J, BEACH ML, JONES RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diag. Microb. Inf. Dis. (2001) 40:173-177.
   Google Scholar
• CERCENADO E, CERCENADO S, BOUZA E: In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob. Agents Chemother. (2003) 47:2644-2645.
   Web of Science ®Google Scholar
• EDLUND C, NORD CE: In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin. Microb. Inf. (2000) 6:158-163.
   Google Scholar
• GALES AC, JONES RN: Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diag. Microb. Inf. Dis. (2000) 36:19-36.
   Google Scholar
• GOLDSTEIN EJC, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL K: Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. (2000) 44:2747-2751.
   Web of Science ®Google Scholar
• HOELLMAN DB, PANKUCH GA, JACOBS MR, APPELBAUM PC: Antipneumococcal activity of GAR 936, a new glycylcycline, compared to those of nine other agents against penicillin susceptible and resistant pneumococci. Antimicrob. Agents Chemother. (2000) 44:1085-1088.
   Web of Science ®Google Scholar
• JACOBUS NV, MCDERMOTT LA, RUTHAZER R, SNYDMAN DR: In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. (2004) 48:1034-1036.
   Web of Science ®Google Scholar
• KITZIS MD, LY A, GOLDSTEIN FW: In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2004) 48:366-367.
   Web of Science ®Google Scholar
• LOW DE, KIREISWIRTH BN, WEISS K, WILLEY BM: Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int. J. Antimicrob. Agents (2002) 20:220-222.
   Web of Science ®Google Scholar
• PACHON-IBANEZ ME, JIMENEZ-MEJIAS ME, PICHARDO C, LLANOS AC, PACHON J: Activity of tigecycline (GAR-936) against acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. (2004) 48:4479-4481.
   Web of Science ®Google Scholar
• PATEL R, ROUSE MS, PIPER KE, STECKELBERG JM: In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diag. Microb. Inf . Dis. (2000) 38:177-179.
   Google Scholar
• PETERSEN PJ, BRADFORD PA: Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. (2005) 49:3910-3918.
   Web of Science ®Google Scholar
• PETERSEN PJ, BRADFORD PA, WEISS WJ, MURPHY TM, SUM PE, PROJAN SJ: In vitro and in vivo activities of tigecycline (GAR-936) daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46:2595-2601.
   Web of Science ®Google Scholar
• RHOMBERG PR, JONES RN: In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR-936, tested against clinical isolates of Mycobacterium marinum. Diag. Microb. Inf. Dis. (2002) 42:145-147.
   Google Scholar
• ROBLIN PM, HAMMERSCHLAG, MR: In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. InterJ. Antimicrob. Agents (2000) 16:61-63.
   Web of Science ®Google Scholar
• WALLACE JR RJ, BROWN-ELLIOT BA, CRIST CJ, WALLACE RJ: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of Nontuberculous mycobacteria. Antimicrob. Agents Chemother. (2002) 46:3164-3167.
   Web of Science ®Google Scholar
• EDELSTEIN PH, WEISS WJ, EDELSTEIN MAC: Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. (2003) 47:533-540.
   Web of Science ®Google Scholar
• LEFORT A, LAFAURIE M, MASSIAS L et al.: Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother (2003) 47:216-222.
   Web of Science ®Google Scholar
• NANNINI EC, PAI SR, SINGH KV, MURRAY BE: Activity of tigecycline (GAR-936) a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob. Agents Chemother. (2003) 47:529-532.
   Web of Science ®Google Scholar
• VAN OGTROP ML, ANDES D, STAMSTAD TJ et al.: In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicro. Agents Chemother. (2000) 44:943-949.
   PubMed Web of Science ®Google Scholar
• YIN LY, LAZZARINI L, LI F, STEVENS CM, CALHOUN JH: Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J. Antimicrob Chemother (2005) 55:995-1002.
   Google Scholar
• SOLOMKIN JS, MAZUKI JE, BARON EJ: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. (2003) 37:997-1005.
   Google Scholar
• CALANDRA GB, NORDEN C, NELSON JD, MADER JT: Evaluation of new anti-infective drugs for the treatment of intra-abdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. (1992) 15 (Suppl) 1:S33-42.
   Google Scholar
• NO AUTHORS LISTED: European society of clinical microbiology and infectious disease. European guideline for the clinical evaluation of anti-infective drug products. (1993).
   Google Scholar
• ELLIS-GROSSE EJ, BABLINCHAK T, DARTOIS N, ROSE G, LOH E: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. (2005) 41:S341-353.
   Google Scholar
• BABINCHAK T, ELLIS-GROSSE EJ, DARTOIS N, ROSE GM, LOH E: The efficacy and safety of tigecycline for the treatment of complicated intra abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. (2005) 41:S354-66.
   Google Scholar
• ELLIS-GROSSE EJ, BRADFORD PA, LOH E: Tigecycline in patients with methicillin-resistant Staphylococcus aureus (MRSA) including community acquired (CA)-MRSA – experience from Phase 3 clinical trials. Abstract 533. Infectious disease society of America Congress September (2005) San Diego, CA.
   Google Scholar
• ELLIS-GROSSE EJ, BRADFORD PA, LOH E: Tigecycline in patients with extended-spectrum β-lactamases (ESBL) producing-bacteria – experience from Phase 3 clinical trials. Abstract 531. infectious disease society of America Congress September (2005) San Diego, CA.
   Google Scholar
• MAROKO R, DARTOIS N, BABINCHAK T, ELLIS-GROSSE EJ: safety and tolerability of tigecycline in Phase 3 Trials. Abstract 1786 supplement J. Clin. l Microbiol. Infec. (CMI) ECCMID (2006) Nice, France.
   Google Scholar
• WYETH PHARMACEUTICALSINC: Tigecycline, United States Package Insert, date 06/05. Philadelphia, PA 19101.
   Google Scholar
• DARTOIS N, GANDJINI H, ELLIS-GROSSE EJ: Tigecycline is as effective as levofloxacin in treating patients with community-acquired pneumonia. Abstract O223 Supplement to J. Clin. Microbiol. Infect. (CMI) ECCMID (2006) Nice, France.
   Google Scholar
• DUKART G, COOPER A, ELLIS-GROSSE EJ: Tigecycline (TGC): a safety and efficacy study in patients (Pts) with infections caused by methicillin resistant Staphylococcus aureus (MRSA). Abstract # L1213. 46th Interscience Conference on Antimicrob. Agents Chemother., San Diego, CA, Sept 26-29 (2006).
   PubMedGoogle Scholar